We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -1.36% | 7.26 | 7.11 | 7.26 | 7.40 | 7.045 | 7.40 | 1,705,347 | 00:50:41 |
From May 2021 to May 2024
Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.
Conference Call Information:
| Date: | Wednesday, November 10 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | (844) 615-6509 |
| International Dial-in: | (918) 922-3148 |
| Conference ID: | 5783655 |
| Webcast: | https://edge.media-server.com/mmc/p/zgrrmubx |
About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcellâ„¢). For more information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Investor and Media Contact:Will BrownChief Financial OfficerPhone: 240-654-1450wbrown@altimmune.com
Â
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
